Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Prevalence of Complementary and Alternative Medicine Use and Its Associated Factors among Iranian Diabetic Patients: A Cross-Sectional Study","authors":"Fereshteh Ghorat ,&nbsp;Seyed Hamdollah Mosavat ,&nbsp;Samaneh Hadigheh ,&nbsp;Seyed Amin Kouhpayeh ,&nbsp;Mohammad Mehdi Naghizadeh ,&nbsp;Ali Akbar Rashidi ,&nbsp;Mohammad Hashem Hashempur","doi":"10.1016/j.curtheres.2024.100746","DOIUrl":"10.1016/j.curtheres.2024.100746","url":null,"abstract":"<div><h3>Objective</h3><p>This cross-sectional study aimed to assess the prevalence of complementary and alternative medicine (CAM) use and its associated factors among diabetic patients in Fasa, a city in southern Iran.</p></div><div><h3>Methods</h3><p>Data were collected from diabetic patients who visited the endocrinology clinics at Fasa University of Medical Sciences. A structured questionnaire was administered to gather information on CAM use, including the types of CAM modalities used, and reasons for use. The patient's demographic and clinical characteristics, such as age, gender, duration of diabetes, glycosylated hemoglobin (HbA1c) levels, and quality of life (QoL) were also recorded. Descriptive statistics were used to determine the prevalence of CAM use, while logistic regression analysis was employed to identify factors associated with CAM use.</p></div><div><h3>Results</h3><p>A total of 376 diabetic patients participated in the study, with more than 89% reporting CAM use within the past year. Herbal preparations were the most commonly used type of CAM, with a prevalence rate of 99.4%. Factors associated with CAM use included patients’ psychological health, attitude towards the safety of CAM, belief in the synergistic effects of combining routine medications with CAM, and previous positive experiences with CAM.</p></div><div><h3>Conclusion</h3><p>The high prevalence of CAM use highlights the importance of considering it in diabetes management and the need for healthcare professionals’ engagement in open discussions with patients about their CAM practices. Understanding the factors influencing CAM use can inform healthcare providers and policymakers in developing appropriate strategies for integrating CAM approaches into conventional diabetes care.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100746"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X2400016X/pdfft?md5=87cb751d90a8f5671cf2b9c95707dc6a&pid=1-s2.0-S0011393X2400016X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140268359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro Inhibitory Effect of Nigella sativa L. Extracts on SARS-COV-2 Spike Protein-ACE2 Interaction","authors":"Najma Ali ,&nbsp;Asha Caroline Cyril ,&nbsp;Anagha Parambath ,&nbsp;Cijo George Vazhappilly ,&nbsp;Reem Kais Jan ,&nbsp;Haneen Aburamadan ,&nbsp;Fatemeh Akbarpoor ,&nbsp;S. M. Shariar Islam ,&nbsp;Fazilatun Nessa ,&nbsp;Yosra Lozon ,&nbsp;Noushad Karuvantevida ,&nbsp;Rajan Radhakrishnan","doi":"10.1016/j.curtheres.2024.100759","DOIUrl":"10.1016/j.curtheres.2024.100759","url":null,"abstract":"<div><h3>Ethnopharmacological relevance</h3><div>A catastrophic outbreak of severe acute respiratory syndrome (SARS-CoV-2; Coronavirus disease-19; COVID-19) was first detected in Wuhan, Hubei Province, China, in December 2019. Many experimental and clinical studies have focused on the effectiveness of medicinal plants such as <em>Nigella sativa</em> (NS) in combating SARS-CoV-2. In this study, we aimed to evaluate the <em>in vitro</em> effect of NS seed extract on SARS-CoV-2 spike protein (S1)-angiotensin-converting enzyme 2 (S-ACE2) interaction.</div></div><div><h3>Materials and methods</h3><div>NS seed extracts used for the assay were prepared in chloroform, ethanol, and water by Soxhlet extraction and recovered by rotary evaporation. The inhibition percentage of S1-ACE2 interaction was analyzed using ELISA-SARS-CoV-2 S1 Protein-ACE2 Binding Inhibitor Screening Kit. Chemical finger-printing of the extracts was done using RP-HPLC.</div></div><div><h3>Results</h3><div>Significant concentration-dependent inhibition of the S1-ACE2 interaction was observed with chloroform, ethanol, and water extracts, ranging from 0.01 to 10 mg/ml. The <em>P</em>-values for the extracts were as follows: 0.0055, 0.0937, 0.0013, and 0.0003 for chloroform extract; 0.0876, 0.0703, 0.0183, and 0.0071 for ethanol extract; and 0.0915, 0.0312, 0.0006, and 0.0006 for water extract. The 50% inhibitory concentration (IC50) was determined to be 0.132 mg/ml, 0.288 mg/ml, and 4.06 mg/ml for chloroform, ethanol, and water extracts, respectively.</div></div><div><h3>Conclusion</h3><div>The <em>in vitro</em> analysis utilizing SARS-CoV2 spike (S1) and ACE2 proteins proved that NS seed extracts have the potential to inhibit the S-ACE2 interaction, which warrants further studies that could lead to potential drug discovery for SARS-CoV2 infection.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100759"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142701190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis","authors":"Reza Abniki MS ,&nbsp;Amirhossein Tashakor MS ,&nbsp;Melika Masoudi PhD ,&nbsp;Davood Mansury PhD","doi":"10.1016/j.curtheres.2023.100723","DOIUrl":"10.1016/j.curtheres.2023.100723","url":null,"abstract":"<div><h3>Background</h3><p>Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from <em>Klebsiella pneumoniae</em>.</p></div><div><h3>Objective</h3><p>The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli.</p></div><div><h3>Methods</h3><p>After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus.</p></div><div><h3>Results</h3><p>The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%–0.182%).</p></div><div><h3>Conclusions</h3><p>The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100723"},"PeriodicalIF":1.9,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000322/pdfft?md5=4a99ef11eb23e0a423d533ad9cd718f3&pid=1-s2.0-S0011393X23000322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136128260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy-Associated Spontaneous Coronary Artery Dissection in Women: A Literature Review","authors":"Katherine Zeven MD Class of 2025","doi":"10.1016/j.curtheres.2023.100697","DOIUrl":"10.1016/j.curtheres.2023.100697","url":null,"abstract":"<div><h3>Background</h3><p>Spontaneous coronary artery dissection (SCAD) primarily affects women younger than age 50 years, is often misdiagnosed or undiagnosed, and research on this topic is limited.</p></div><div><h3>Objective</h3><p>A literature review was conducted to identify unique factors that can facilitate pregnancy-related SCAD (P-SCAD) diagnosis as well as differentiate it from nonpregnancy-related SCAD (NP-SCAD).</p></div><div><h3>Methods</h3><p>A literature search was conducted on PubMed, Medline, Embase, The Cochrane Database of Systematic Reviews, and Google Scholar databases that focused on NP-SCAD and P-SCAD cases reported in North America between 2006 and 2021 using the terms <em>spontaneous coronary artery dissection, misdiagnosis</em>, and <em>women</em>, along with <em>postpartum</em> and <em>pregnancy</em>. The Let Evidence Guide Every New Decision quality assessment tool was applied to all reviews.</p></div><div><h3>Results</h3><p>A total of 108 journal articles reporting on individual cases, case series examining independent SCAD registries, as well as literature reviews were identified. These included 1547 SCAD cases in women, 510 of which were identified as P-SCAD. SCAD occurs predominantly in women, and thus presents a diagnostic challenge because women are not typically considered at risk for developing cardiovascular diseases and may present with symptoms that mimic other medical conditions. This issue is further exacerbated when SCAD develops during pregnancy or the postpartum period (ie, P-SCAD to differentiate it from SCAD occurring in other periods of woman's life such as NP-SCAD) because P-SCAD patients often present with less typical cardiac symptoms yet tend to experience more severe illness that can jeopardize their health and that of their baby. P-SCAD was associated with higher ST-segment elevation myocardial infarction rates, higher troponin levels, and a greater risk of cardiogenic shock compared with NP-SCAD cohorts. It was also evident that the failure rates associated with invasive procedures such as percutaneous coronary intervention and coronary artery bypass graft surgery were higher in P-SCAD patients, whereas the mortality rates are comparable to NP-SCAD cohorts if diagnosed and treated appropriately.</p></div><div><h3>Conclusions</h3><p>Because younger women are rarely screened, they are at greater risk from SCAD, especially if this condition develops during pregnancy or ≤30 days following delivery. It is essential that medical professionals providing care for pregnant women understand P-SCAD risk factors and provide medical counseling for pregnant women or those planning a pregnancy to be better equipped to recognize its more subtle signs and symptoms, thus facilitating timely specialist referral, diagnosis, and treatment. (<em>Curr Ther Res Clin Exp</em>. 2023; 84:XXX–XXX)</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100697"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Curative Effects of Aqueous Extracts of Cissus quadrangularis (Vitaceae) and Jatropha gossypiifolia (Euphorbiaceae) on Acetaminophen-Induced Liver Injury in Mice","authors":"Romeo Joel Guemmogne Temdie BSc, MSc, Ph.D ,&nbsp;Edwige Ymele Chiogo Vouffo BSc, MSc, Ph.D ,&nbsp;Borris Rosnay Tietcheu Galani BSc, MSc, Ph.D ,&nbsp;Bertrand Dabole Ladane BSc, MSc ,&nbsp;Josee Bianzoumbe BSc, MSc ,&nbsp;Marc Germain Kuum Minoue BSc, MSc, Ph.D ,&nbsp;Fidèle Ntchapda BSc, MSc, Ph.D ,&nbsp;Theophile Dimo BSc, MSc, Ph.D","doi":"10.1016/j.curtheres.2023.100716","DOIUrl":"https://doi.org/10.1016/j.curtheres.2023.100716","url":null,"abstract":"<div><h3>Background</h3><p>Acetaminophen-induced liver injury remains a significant public health problem because available treatments are limited due to their adverse effects. Medicinal plants, which are an important source of bioactive molecules, could be an alternative treatment for liver disease.</p></div><div><h3>Objective</h3><p>This study was designed to investigate the curative effect of aqueous extracts of <em>Cissus quadrangularis</em> (Vitaceae) and <em>Jatropha gossypiifolia</em> (Euphorbiaceae) on acetaminophen-induced liver injury in mice.</p></div><div><h3>Methods</h3><p>Mice were divided into groups and treated with distilled water, silymarin (50 mg/kg), a reference hepatoprotective agent, and aqueous extracts of <em>C quadrangularis</em> and <em>J gossypiifolia</em> (50 and 100 mg/kg, PO, respectively). These substances were given as a single daily dose 4 hours after acetaminophen administration (300 mg/kg, PO) for 2 days. Mice were humanely put to death 24 hours after the last dose and serum alanine aminotransferase and aspartate aminotransferase activities, total bilirubin and protein levels, reduced glutathione, superoxide dismutase, malondialdehyde, catalase, and nitrite tissue levels were assessed. Histology of the livers of the mice was performed by hematoxylin and eosin staining.</p></div><div><h3>Results</h3><p>Acetaminophen administration induced a significant (<em>P</em> &lt; 0.05) mean (SEM) body weight loss (–14.45% [5.92%]), a significant elevation of alanine aminotransferase activity (15.08%), total protein and bilirubin levels (25.80%), and a significant (<em>P</em> &lt; 0.05) increase in liver superoxide dismutase (67.71%), catalase (63.00%), glutathione (40.29%), malondialdehyde (30.67%), and nitrite levels compared with the control group. In curative treatment, <em>C quadrangularis</em> and <em>J gossypiifolia</em> (50 and 100 mg/kg) significantly (<em>P</em> &lt; 0.05) reduced mean (SEM) body weight loss (16.67% [7.16%] and 1.25% [0.51%], respectively), serum alanine aminotransferase activity (17.62% and 11.14%, respectively), bilirubin level (29.62% and 49.14%, respectively) compared with acetaminophen group, and <em>J gossypiifolia</em> normalized serum total protein level. Both extracts significantly (<em>P</em> &lt; 0.05) reduced the levels of glutathione and malondialdehyde and normalized that of nitrite, superoxide dismutase, and catalase compared with the acetaminophen group. Hepatocyte necrosis and inflammatory cell infiltration were remarkably reduced by the plant extracts.</p></div><div><h3>Conclusions</h3><p>The results obtained are evidence in favor of the development of a formulation based on the extracts of these plants against liver diseases.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100716"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49812943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ideal Features of Topical Antibiotic Therapy for the Treatment of Impetigo: An Italian Expert Consensus Report","authors":"Iria Neri MD ,&nbsp;Michele Miraglia del Giudice MD ,&nbsp;Andrea Novelli MD ,&nbsp;Giuseppe Ruggiero MD ,&nbsp;Giovanni Pappagallo MD, MPH ,&nbsp;Luisa Galli MD","doi":"10.1016/j.curtheres.2022.100690","DOIUrl":"10.1016/j.curtheres.2022.100690","url":null,"abstract":"<div><h3>Background</h3><p>A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information re- garding their appropriate use and prescription that should be considered in clinical practice for impetigo management.</p></div><div><h3>Objective</h3><p>A group of Italian experts in impetigo medical care sought to define 10 statements to describe the ideal characteristics of the best local antibiotic treatments, and to provide relevant information regarding their appropriate use and prescription that should be considered in clinical practice for impetigo management.</p></div><div><h3>Methods</h3><p>A consensus on ideal features of antibiotic therapy for the treatment of impetigo was appraised by an online Delphi-based method, based on a panel of 61 infectious disease specialists, pediatricians, and dermatologists coordinated by a scientific committee of 5 experts specializing in impetigo management.</p></div><div><h3>Results</h3><p>Full or very high consensus was reached on the 10 statements identified to describe the characteristics of the best hypothetic antibiotic therapy for impetigo together with indications for appropriate antibiotics use.</p></div><div><h3>Conclusions</h3><p>Several criteria have to be considered when selecting topical antibacterial therapy for impetigo. Beyond efficacy and safety, antimicrobial susceptibility and pharmacological characteristics of the agent are essential points. Formulation of the antimicrobial product is fundamental, as well as patient and caregiver preference, to facilitate therapeutic adherence, to achieve the infection control, and to obtain the best benefit from treatment (<em>Curr Ther Res Clin Exp.</em> 2023; 84:XXXXXX).</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100690"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/95/main.PMC9881045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10589466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation","authors":"David Farchadi MD, MS ,&nbsp;Neal E. Slatkin MD ,&nbsp;Nancy Stambler DrPH ,&nbsp;Robert J. Israel MD ,&nbsp;Michael Matus MD","doi":"10.1016/j.curtheres.2023.100694","DOIUrl":"10.1016/j.curtheres.2023.100694","url":null,"abstract":"<div><h3>Background</h3><p>Opioid-induced constipation (OIC) may increase the risk of fecal impaction and mortality in patients with advanced illness. Methylnaltrexone (MNTX) is efficacious for OIC.</p></div><div><h3>Objective</h3><p>The purpose of this analysis was to evaluate cumulative rescue-free laxation response with repeat MNTX dosing in patients with advanced illness who were refractory to current laxative regimens and to assess the influence, if any, of poor functional status on response to MNTX treatment.</p></div><div><h3>Methods</h3><p>This analysis included pooled data from patients with advanced illness and established OIC who were on a stable opioid regimen in a pivotal, randomized, placebo (PBO)-controlled clinical trial (study 302 [NCT00402038]) or a randomized, PBO-controlled Food and Drug Administration-required postmarketing study (study 4000 [NCT00672477]). Patients in study 302 received subcutaneous MNTX 0.15 mg/kg or PBO every other day, whereas those in study 4000 received MNTX 8 mg (body weight ≥38 to &lt;62 kg), MNTX 12 mg (body weight ≥62 kg), or PBO every other day. Outcomes included cumulative rescue-free laxation rates at 4- and 24-hours postdose for the first 3 doses of study drug and time to rescue-free laxation. To assess if functional status influenced treatment outcomes, we performed a secondary analysis on the outcomes stratified by baseline World Health Organization/Eastern Cooperative Oncology Group performance status, pain scores, and safety.</p></div><div><h3>Results</h3><p>One hundred eighty-five patients received PBO and 179 patients received MNTX. The median age was 66.0 years, 51.5% were women, 56.5% had a baseline World Health Organization/Eastern Cooperative Oncology Group performance status score &gt;2, and 63.4% had a primary diagnosis of cancer. Cumulative rescue-free laxation rates were significantly higher with MNTX than PBO 4- and 24-hours after doses 1, 2, and 3 (<em>P</em> &lt; 0.0001), and between-treatment comparisons remained significant (<em>P</em> &lt; 0.0001) regardless of performance status. The estimated time to first rescue-free laxation was shorter for patients receiving MNTX versus PBO. No new safety signals were identified.</p></div><div><h3>Conclusions</h3><p>Repeated use of MNTX represents a safe and effective treatment for OIC in patients with advanced illness regardless of baseline performance status. ClinicalTrials.gov identifier: NCT00672477. (<em>Curr Ther Res Clin Exp</em>. 2023; 84:XXX–XXX)</p><p>© 2023 Elsevier HS Journals, Inc.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100694"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/db/main.PMC9981808.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9412747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Subchronic Propofol Administration on the Proliferation and Differentiation of Neural Stem Cells in Rat Hippocampus","authors":"Cheng Chang MD ,&nbsp;Wenya Bai MD ,&nbsp;Junjie Li MD ,&nbsp;Siying Huo MD ,&nbsp;Tinghua Wang PhD ,&nbsp;Jianlin Shao PhD","doi":"10.1016/j.curtheres.2023.100691","DOIUrl":"10.1016/j.curtheres.2023.100691","url":null,"abstract":"<div><h3>Background</h3><p>Although controversial, experimental data suggest the use of propofol may be associated with neurotoxicity. The mechanisms responsible for propofol neurotoxicity in animals are not yet clear.</p></div><div><h3>Objective</h3><p>This study aimed to determine the effects of propofol on the proliferation of neural stem cells in rat hippocampus and the mechanisms underlying these effects.</p></div><div><h3>Methods</h3><p>Forty-five adult male Sprague-Dawley rats were randomly divided into 5 groups: Control (N group), intralipid (V group), 30 mg/kg propofol (Prop30 group), 60 mg/kg propofol (Prop60 group), and 120 mg/kg propofol (Prop120 group). The rats in all groups received 5, once daily intraperitoneal injections. For each of the 5 days, the N group received 6 mL/kg normal saline, the V group received 6 mL/kg fat emulsion, the Prop30 group received 30 mg/kg propofol, the Prop60 group received 60 mg/kg propofol, and the Prop120 group received 120 mg/kg propofol. Memory function was scored daily using the Morris water maze test. Immunofluorescence staining was used to histologically monitor the proliferation and differentiation of the rats’ hippocampal neural stem cells, and real time quantitative polymerase chain reaction and Western blotting were used to determine the expression of Notch3, Hes1, and Hes5.</p></div><div><h3>Results</h3><p>Compared with the N group, the Prop120 group exhibited reduced learning and memory, whereas there were no significant differences for the Prop60 group. The number of β-tubulin III⁺ cells increased in the Prop60 group, but decreased in the Prop120 group. Compared with the N group, the relative expression of Notch3 and Hes5 increased significantly in the Prop60 group, whereas this expression decreased in the Prop120 group.</p></div><div><h3>Conclusions</h3><p>These data demonstrate that repeated, subchronic (5 days) intraperitoneal injections of 60 mg/kg propofol can effectively promote rat hippocampal neural stem cells proliferation and differentiation, and that this is likely mediated by its effects on the Notch3-Hes5 pathway.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"98 ","pages":"Article 100691"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/41/main.PMC9925857.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10748478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review","authors":"Pegah Shakib PhD ,&nbsp;Masoomeh Zivdari MSc ,&nbsp;Amal Khudair Khalaf PhD ,&nbsp;Abdolrazagh Marzban PhD ,&nbsp;Mazdak Ganjalikhani-Hakemi PhD ,&nbsp;Jahanbakhsh Parvaneh MD ,&nbsp;Hossein Mahmoudvand PhD ,&nbsp;Kourosh Cheraghipour PhD","doi":"10.1016/j.curtheres.2023.100715","DOIUrl":"https://doi.org/10.1016/j.curtheres.2023.100715","url":null,"abstract":"<div><h3>Background</h3><p>Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus <em>Schistosoma</em>. The current drugs for treating schistosomiasis are associated with some side effects.</p></div><div><h3>Objective</h3><p>The aim of this systematic study was an overview of the treatment of diseases caused by <em>Schistosoma</em> based on nanoparticles.</p></div><div><h3>Methods</h3><p>In the present systematic research with keywords “<em>Schistosoma</em>”, “parasitism”, “anti-<em>Schistosoma</em> activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “<em>in vitro</em>”, and “<em>in vivo</em>” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.</p></div><div><h3>Results</h3><p>In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against <em>Schistosoma</em> were gold nanoparticles (22%).</p></div><div><h3>Conclusions</h3><p>The results indicate the high potential of various nanoparticles, including metal nanoparticles, against <em>Schistosoma</em>. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. <em>Ther Res Clin Exp</em>. 2023; XX:XXX–XXX).</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100715"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49812949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Antipsychotic Agents on the Sexuality of Patients Diagnosed with Schizophrenia","authors":"Jaballah Fares ,&nbsp;Ferhi Mohamed ,&nbsp;Zgueb Yosra ,&nbsp;Hazem Oumaya ,&nbsp;Bouzid Riadh ,&nbsp;Mannaii Jihenne","doi":"10.1016/j.curtheres.2023.100722","DOIUrl":"https://doi.org/10.1016/j.curtheres.2023.100722","url":null,"abstract":"<div><h3>Background</h3><p>Sexuality is a natural component of human behavior. The general population has been extensively studied since the first half of the 20th century. On the other hand, regarding patients treated for schizophrenia, discussing sexual disorders was initially considered inappropriate because it was believed they should not be sexually active. Given these findings, this work proposes to study the sexuality of patients with schizophrenia.</p></div><div><h3>Objectives</h3><p>Our objectives were to assess the sexuality of patients with schizophrenia, to identify factors associated with sexual dysfunction among these patients, and to determine practitioners' attitudes toward the sexuality of our study population.</p></div><div><h3>Methods</h3><p>This is a cross-sectional study carried out in the Psychiatry Department of Kairouan (outpatient department), including 46 patients diagnosed with schizophrenia. A pre-established information sheet was completed for each patient recruited, including sociodemographic and clinical data; on the other hand, 3 scales ensured a sexual psychometric evaluation: Psychotropic-Related Sexual Dysfunction Questionnaire, Arizona Sexual Experiences Scale, and Changes in Sexual Functioning Questionnaire-Male Clinical Version.</p></div><div><h3>Results</h3><p>Concerning the evaluation of sexuality according to the scales used, sexual dysfunction according to Psychotropic-Related Sexual Dysfunction Questionnaire scores was observed in 31 patients (67.4%). According to Arizona Sexual Experiences Scale scores, 24 patients (52%) had a sexual dysfunction, and for the total score of the Changes in Sexual Functioning Questionnaire-Male Clinical Version, 27 patients (58.7%) had a sexual dysfunction. We cannot confirm the existence of a relationship between the dose of the current treatment (in chlorpromazine equivalent) used and the results of the test assessing sexuality. In addition to these results, we can deduce the existence of a statistically significant association between the antipsychotic agent used and the results of the Psychotropic-Related Sexual Dysfunction Questionnaire only.</p></div><div><h3>Conclusions</h3><p>We recommend that screening for sexual dysfunction in patients followed for schizophrenia should be systematic, regardless of the antipsychotic molecule type and dosage. In this regard, we recommend the establishment of a better therapeutic relationship between caregivers and patients with schizophrenia, based on empathy and trust, so that the latter feel comfortable enough to address the sexual dimension in general and sexual dysfunction in particular.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100722"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000310/pdfft?md5=24d748d27ab5bad52a06908385280f93&pid=1-s2.0-S0011393X23000310-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92114458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}